For Celia Lau, the value of the research at B.C. Children’s Hospital is not hard to measure. She sees it every day in the face of her vibrantly healthy 10-year-old son, Justin. Without a personalized genetic treatment developed at the hospital’s research institute, Justin may not have survived his illness. Lau gave birth to her first child, Cameron, in 2004.…
Read More
Researchers from the University of British Columbia are retracting their scientific paper linking aluminum in vaccines to autism in mice, because one of the co-authors claims figures published in the study were deliberately altered before publication — an issue he says he realized after allegations of data manipulation surfaced online. The professor also told CBC News there’s no way to know “why” or “how” the figures were…
Read More
ICORD PhD student Seth Tigchelaar is representing UBC in the international Universitas 21 3-Minute Thesiscompetition. The 3 Minute Thesis (3MT) challenges graduate students to explain their research to a non-scientific audience in three minutes or fewer. Seth, who is working on his PhD with Dr. Brian Kwon, is studying how biomarkers can help predict the severity of spinal cord injury. In February of this…
Read More
The Centre for Drug Research and Development (CDRD), Canada’s national drug development and commercialization centre, is pleased to announce the appointments of Dr. Francois Bénard and Ms. Nancy Harrison as Directors of the organization. Dr. Bénard is Vice President of Research at the BC Cancer Agency where he is responsible for setting and facilitating a comprehensive cancer research strategy and…
Read More
At the EATRIS’ Translational Medicine 2017 Conference, and at the height of Global Biotech Week, it was announced that five of the world’s top translational science organizations representing the European Union, the United Kingdom, the United States, Canada, and Australia have joined forces under the new banner of Translation Together. This new collaboration will enable the leveraging of complementary scientific and…
Read More
This week, Conversations That Matter features the remarkable Dr. Allen Eaves, the founder, CEO and President of STEMCELL Technologies, Canada’s most successful biotech company. A firm that is playing a pivotal role in fostering a community of biotech startups. Eaves says, “we’re very keen to support an ecosystem of biotechnology here and be closely related with the universities, especially UBC…
Read More

From Patient to Survivor: Madeline’s Inspiration to Study Pediatric Cancer

In 2012, 14-year-old Madeline Lauener received a stem cell transplant from her sister as treatment for a rare type of blood cancer. Five years later, she’s at BC Children’s Hospital, taking part in research that aims to help kids diagnosed with cancer. “I joined the Summer Student Research Program because I wanted to learn and be involved in the cancer…
Read More
Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to “reboot” the body’s innate immune system, has identified specific ulcerative colitis (UC) genetic markers that may predict response to QBECO SSI therapy and important immunological biomarkers that may be used to track response. These discoveries came from genetic and cytokine analyses of Qu Biologics’…
Read More

Distinguished Research Leaders Join MSFHR’s Research Leaders Forum

MSFHR is delighted to convene the first MSFHR Research Leaders Forum, a group of internationally recognized researchers who will advise the Foundation on the trends, challenges and opportunities shaping health research at provincial, national and international levels. Following a nomination process, the MSFHR Board of Directors has selected 15 distinguished researchers from across the broad spectrum of BC health research to…
Read More
InMed Pharmaceuticals, Inc., a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today an update to its investors and stakeholders on the significant advancements in its proprietary technology for the microbial biosynthesis of cannabinoids. InMed has successfully demonstrated that it can selectively produce all four “gateway” cannabinoids using genetically engineered microorganisms. These molecules can be…
Read More